Chris is an outstanding leader who brings vast experience across multiple industries, from his career at McKinsey & Company, his accomplishments as a visionary entrepreneur, and his success as an astute investor.
SAN DIEGO (PRWEB) January 23, 2020
Cytonus Therapeutics Inc. today announced the appointment of Christopher Thorne as Chairman. Mr. Thorne is a noted investor, tech entrepreneur, and former senior management consultant at McKinsey & Company who holds three Harvard degrees. He serves as Executive Chairman of Broadline Capital, the global alternative investment firm.
“Chris Thorne has exceptional business acumen with a proven track record in developing purpose-led businesses, driving innovation, and reinforcing a commitment to corporate responsibility,” commented Cytonus’ Founder and CEO, Remo Moomiaie-Qajar, MD. “He has extensive directorship experience at both publicly-listed corporations and privately-held ventures, as well as 501(c)(3) nonprofit organizations. All of these attributes, combined with his excellent people engagement and strategic insight, gives us confidence that Chris will help build a strong culture as we work together toward our shared vision for the Company and accelerate the development of our innovative platform of products to improve the health and lives of people across the globe.”
“Cytonus is delighted to have appointed Chris Thorne as our Chairman after a thorough and rigorous selection process,” commented Cytonus’ Founder and Chief Scientific Officer, Richard Klemke, PhD. “Chris is an outstanding leader who brings vast experience across multiple industries, from his career at McKinsey & Company, to his accomplishments as a visionary entrepreneur, and his success as an astute investor.”
Mr. Thorne will lead Cytonus’ corporate board of directors and will serve as an independent non-executive director for the company.
About Cytonus Therapeutics Inc.
Cytonus Therapeutics Inc. is a San Diego based biotech company that has developed a vast platform of proprietary immunotherapeutic products to treat a wide range of medical conditions including cancers, infectious diseases, inflammatory diseases and cognitive disorders, and to improve patient outcomes. Its proprietary Cargocyte™ technologies are next-generation biomolecular delivery devices which have numerous medical applications across unmet therapeutic areas. Cargocytes™ are engineered to safely transport a multiplicity of therapeutic payloads into difficult-to-reach targeted tissues, and can be programmed to deliver selective, potent, and controllable "off-the-shelf" therapies. Cytonus' vast platform of therapeutics and vaccines has the potential to improve the health and lives of people with life-threatening conditions. For more information, we invite you to visit the Cytonus website at https://Cytonus.com. Please follow us on Cytonus on LinkedIn and on Twitter at: @CytonusTx.
Statements in this news release other than strictly historical facts, such as statements about Cytonus' plans and strategies, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for its products, are forward-looking statements. The words "believe," "expect," "aim," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Such statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results due to many factors, including regulatory and development risks. The company undertakes no obligation to publicly update or revise any forward-looking statement. This news release is neither an offer to sell, nor the solicitation of any offer to purchase, any security.
Join Cytonus on LinkedIn and follow its Twitter account at: @CytonusTx